Promock

## RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/535,814C
Source:	, 1600 RUSH
Date Processed by STIC:	6/10/2002
	• •

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: <a href="mailto:patin21help@uspto.gov">patin21help@uspto.gov</a> or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: <a href="mailto:patin3help@uspto.gov">patin3help@uspto.gov</a> or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<a href="http://www.uspto.gov/web/offices/pac/checker">http://www.uspto.gov/web/offices/pac/checker</a>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom:

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
- Hand Carry directly to:
   U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202

U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

 Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



1600

RAW SEQUENCE LISTING

DATE: 06/10/2002

PATENT APPLICATION: US/09/535,814C

TIME: 15:44:48

Input Set : A:\EP.txt

Output Set: N:\CRF3\06102002\I535814C.raw

6 <140> CURRENT APPLICATION NUMBER: US/09/535,814C

C--> 6 <141> CURRENT FILING DATE: 2000-03-28

0 <110> APPLICANT:

0 <120> TITLE INVENTION:

0 <130> FILE REFERENCE:

6 <160> NUMBER OF SEQ ID NOS: NUMBER OF SEQ ID NOS: 3

## ERRORED SEQUENCES

E--> 8 <210> SEQ ID NO: SEQ ID NO 1 9 <211> LENGTH: LENGTH: 313

E--> 10 <212> TYPE: TYPE: PRT

11 <213> ORGANISM: ORGANISM: Canis familiaris

E--> 13 <400> SEQUENCE: SEQUENCE: 1

15 Met Thr Glu Lys Asn Gln Thr Val Val Ser Glu Phe Val Leu Leu 10 5 18 Gly Leu Pro Ile Asp Pro Asp Gln Arg Asp Leu Phe Tyr Ala Leu E--> 19 16 20 21 Phe Leu Ala Met Tyr Val Thr Thr Ile Leu Gly Asn Leu Leu Ile

40

E--> 22 31 35 24 Ile Val Leu Ile Gln Leu Asp Ser His Leu His Thr Pro Met Tyr E--> 25 46 50 55.

27 Leu Phe Leu Ser Asn Leu Ser Phe Ser Asp Leu Cys Phe Ser Ser E--> 28 61 65 . 70

30 Val Thr Met Pro Lys Leu Leu Gln Asn Met Gln Ser Gln Val Pro 85 80

33 Ser Ile Pro Tyr Ala Gly Cys Leu Thr Gln Met Tyr Phe Phe Leu 95 100

E--> 34 91 36 Phe Phe Gly Asp Leu Glu Ser Phe Leu Leu Val Ala Met Ala Tyr

115 E--> 37 106 110 39 Asp Arg Tyr Val Ala Ile Cys Phe Pro Leu His Tyr Thr Thr Ile

130 E--> 40 121 125

42 Met Ser Pro Lys Leu Cys Phe Ser Leu Leu Val Leu Ser Trp Val 140 145 E--> 43 136

45 Leu Thr Met Phe His Ala Val Leu His Thr Leu Leu Met Ala Arg

160 E--> 46 151 155 48 Leu Cys Phe Cys Ala Asn Thr Ile Pro His Phe Phe Cys Asp Met

175 E--> 49 166 170

51 Ser Ala Leu Leu Lys Leu Ala Cys Ser Asp Thr Gln Val Asn Glu 185 190

54 Leu Val Ile Phe Ile Met Gly Gly Leu Ile Leu Val Ile Pro Phe 205 200 E--> 55 196

**Does Not Comply** Corrected Diskette Needed

	•								6	lel.	te.								
///07 /1207	7/	) — /	ln	sli	<i># =</i>	the.	se c	SEQ Ma	MENC	E LI	STIN 1 hu	e) inl	vė.	reve	tiper	i a	nd :	the	ù
∠141 <b>7</b> <160	)> <del>-NU</del>	MBER	del	ite SEQ	ID N	IOS.	3		sha	- <i>H</i>	on	ly i	hus	reve'		N	spe	me	V
<211	)> <del>SE</del>  > <del>LE</del>	Q ID	<u>NO</u>  ÷- 31	1								id —	lent	itiers	an	1 11	eir r	ESPO.	nse
	?> <del>TY</del> }> <del>OF</del>			Cani	s fa	mili	aris	;			-			l	do	ret	sho	W	
	)> - <del>S</del> E	_													al	phi	bet	ical,	١
Met 1	Thr	Glu	Lys	Asn 5	Gln	Thr	Val	Val	Ser 10	Glu	Phe	Val	Leu	Leu 15		h	eadi	'ng S <sub>J</sub>	)
Gly 16	Leu	Pro	Ile	Asp 20	Pro	Asp	Gln	Arg	Asp 25	Leu	Phe	Tyr	Ala	Leu 30					
Phe 31	Leu	Ala	Met	Tyr 35	Val	Thr	Thr	Ile	Leu 40	Gly	Asn	Leu	Leu	Ile 45					
Ile 46	Val	Leu	Ile	Gln 50	Leu	Asp	Ser	His	Leu 55	His	Thr	Pro	Met	Tyr 60					
Leu 61	Phe	Leu	Ser	Asn 65	Leu	Ser	Рḥе	Ser	Asp 70	Leu	Cys	Phe	Ser	Ser 75					
Val 76	Thr	Met	Pro	Lys 80	Leu	Leu	Gln	Asn	Met 85	Gln	Ser	Gln	Val	Pro 90	e.				
Ser 91	Ile	Pro	Tyr	Ala 95	Gly	Cys	Leu	Thr	Gln 100	Met	Tyr	Phe	Phe	Leu 105					
Phe 106	Phe	Gly	Asp	Leu 110	Glu	Ser	Phe	Leu	Leu 115	Val	Ala	Met	Ala	Tyr 120					
Asp 121		Tyr	Val	Ala 125	Ile	Суѕ	Phe	Pro	Leu 130	His	Tyr	Thr	Thr	Ile 135					
Met 136	Ser	Pro	Lys	Leu 140	Суѕ	Phe	Ser	Leu	Leu 145	Val	Leu	Ser	Trp	Val 150					-
Leu 151		Met	Phe	His 155	Ala	Val	Leu	His	Thr 160		Leu	Met	Ala	Arg 165					
Leu 166	-	Phe	Cys	Ala 170	Asn	Thr	Ile	Pro	His 175	Phe	Phe	Суѕ	Asp	Met 180					
Ser 181		Leu	Leu	Lys 185	Leu	Ala	Cys	Ser	Asp 190		Gln	Val	Asn	Glu 195					
Leu 196		Ile	Phe	Ile 200		Gly	Gly	Leu	Ile 205	Leu	Val	Ile	Pro	Phe 210					
Leu 211		Ile	Ile	Thr 215		Tyr	Ala	Arg	Ile 220	Val	Ser	Ser	Ile	Leu 225					
Lys 226		Pro	Ser	Ala 230		Gly	Ile	Cys	Lys 235		Phe	Ser	Thr	Cys 240					

Gly Ser His Leu Ser Val Val Ser Leu Phe Tyr Gly Thr Val Ile Gly Leu Tyr Leu Cys Pro Ser Ala Asn Asn Ser Thr Val Lys Glu Thr Ile Met Ala Met Met Tyr Thr Val Val Thr Pro Met Leu Asn 280 Pro Phe Ile Tyr Ser Leu Arg Asn Lys Asp Met Lys Gly Ala Leu 295 Arg Arg Val Ile Cys Arg Lys Lys Ile Thr Phe Ser Val 310 <210> SEQ ID NO 2 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Canis familiaris <400> SEQUENCE: 2 Asp Pro Asp Gln Arg Asp Cys 5 <210> SEQ\_ID\_NO 3 <211> <del>LENGTH:</del> 13

<212> TYPE: PRT <213> ORGANISM: Canis familiaris <400> SEQUENCE: 3

Leu Phe Leu Ser Asn Leu Ser Phe Ser Asp Leu Cys Ala 1 5 10

Please consult sample Sequence Listing (attacked) for valid format

```
<110>
               Smith, John: Smithgene Inc.
  <120>
               Example of a Sequence Listing
               10000-10
  <130>
               PCT/EP98/00001
  <140>
  <141/2
               1998-12-31
               US 08/999,999
  <150>
 <151>
               1997-10-15
 <160>
 <170>
               PatentIn version 2.0
 <210>
              1
              389
 <211>
 <212>
              ANG
 <213>
              Paramecium sp.
 <220>
              CDS
 <221>
              (279) . . . (389)
 <222>
 <300>
<301>
              Doc. Richard
              Isolation and Characterization of a Gene Encoding a
<302>
              Protease from Paramecium sp.
<303>
              Journal of Genes
<304>
<305>
<306>
              1-7
<307>
              1988-06-31
<308>
              123456
<309>
              1988-06-31
<400>
                                                                                        60
agetglagte
             attectgtgt
                          cctcttctct
                                        cigggettet
                                                    caccetgeta
                                                                  atcagatete
                                                                                       120
             tettgaccet:
                                        tgcagottca
                                                    caggcaggca
                                                                 ggcaggcagc
agggagagtg
                          cctctgcctt
                                                                                       180
tgatgtggca
             actoctogca
                                                    aggettaggg
                                                                  tgggttccgc
                          gtgccacagg
                                        cttttcagcc
                                                                                       240
cgcggcgcgg ·
             cggcccctct
                                                    ctctcgctct
                                                                 cctctcgctc
                          cgcgctcctc
                                        tcgcgcctct
```

Cease Consult

## Appendix 3, page 2

						٠.					₹.					
998		SEE A		ocag	9099	499999	g ca	gttag	<b>c</b>	atg Het 1	gtt Val				Ser	296
	_									•				,		
ttg	tct	ttc	. 200	tgg	cct	·	ttt	tgt	ttg	ttt	gtt	tgt	ttg	ttc	Caa	344
Leu				Top		Cly			Leu		Val	Cys	Lcu	Phe	Cln	• • •
			1.0			•		15	`				20	•		
						-		•			•					
•										oro		666			•••	
tgt	ccc		-		ccc		cac	tca Ser	tca Ser		Cag			ن <del>نظ</del> ــ	•	389
Cys	Pro	-	-Val	Lèu	Lto	Cys	His	261	261	-DCU	. • • • • • • • • • • • • • • • • • • •	., 35	77311-		•	
•		. 25					30				`:	. ,,		<u> </u>		•
	• 14		•										•			
	4	•									4				·	
<210	ا (۱۶	2						:						. 3	•	
<211	<b>&gt;</b>	. 3.	7						1-	*******	4					
<212	, A.	· Li	R1'							.*						
<213	>	Pa	ramed	ium s	р.					~ V		• • •				
<<00		2			••	•										
Het			Het	Pho	Ser	Leu	Ser	Phe	Lys	Trp	Pro	Cly	Phe	Cys	Leu	
1	VU.	50.		5	361	DCU	36.		10					1.5	500	
• .				•								•		• •		
											-				_	
Phe	Va l	Cys	Lcu	Phe	Cln	Cys	1,10	l.ys	Va l	ren	Pro	Cys	llis	Ser	Ser	
			20					25					30			
Leu	Gln	Pro	۸sn	Leu												
DCU	0111	35	N311	1,00						••						
		, ,														
				•										••		
<210>		3														
<211>		11														
<212>		r'R'														
<213>		۸r۱	tific	ial Sc	dncuc	C										
		•							* ,							
<220>																
<223>		Des	ianco	nent	ide b	ased o	on siz	e and	nola	rity t	o act	asa	1			
		lir	ker L	octwee.	n the	a Loha	and	beta	chain	s of I	rotci	in XY2	١.			
						•										
<400>		3	•							_						
Met	val	Λsn	ren		Pro	Met	His	Thr (		He						
1				5					10							
<210>		٠.												*		
<400>		4														
000		•														

[Annex VIII follows]

table. The numeric identifier shall be used only in the sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifie	Definition r	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other, Names and/or Initials	M v
<120>	Title of Invention		<b>м</b>
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Applica- tion Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date "	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	М
<170>	Software,	Name of software used to create the Sequence Listing	0
<210>	SEQ ID NO: #:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M
	•	,	_

Whether presented sequence moleculc is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/ RNA molecule shall be further described in the <220> to <223> feature section.

<213>

Organism

Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.

<220>

Feature

Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.

M, under the following conditions: if "n,"
"Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGAN-ISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.

<221>

Name/Key

Provide appropriate identifier for feature, pre-ferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6

M, under the [ollowing conditions:=
i[ "n," "Xaa," or
a modified or unusual L-amino
acid or modified
base was used in
a sequence

<222>

Location

Specify location within sequence; where appropriate state number of first and last bases/amino acids

M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

01/14

<223>

Other Information

Other relevant information; four lines maximum

M, under the following conditions:
if "n," "Xaa," or
a modified or unusual L-amino acid
or modified base
was used in a
sequence; if
ORGANISM
is "Artificial
Sequence" or
"Unknown"; if immodicule is combined DNA/RNA-

<300> .

Publication Information

Leave blank after <300>

<301>

**Authors** 

Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials

<302> Title

<303> Journal

<304> Volume

<305> Issue

<306> Pages

<307> Date

Journal date on which data published; specify as yyyy-mm-dd, 100M-yyyy or Season-yyyy

<300> Database Accession Number

Accession number assigned by database including database name

<309> Database Entry Date

Date of entry in O database; specify as yyyy-mm-dd or MMM-yyyy

<310> Patent Document
Number

Document number; for patent-type citations only, Specify as, for example, US 07/999,999 ′ 7

¥0

0

0

0

ο ·

0

0

0

E

01 34

<311> Patent Fil Document (iling Date date, for patenttype citations only; specify as yyyy-mm-dd <312> Publication Date Document publication o. date, for patent-type citations only; specify as yyyy-mm-dd <313> Relevant FROM (position) TO Residues (position) <400> Sequence SEQ ID NO should .:M follow the numeric identilier and should appear on the line preceding the actual sequence

- 5. Section 1.024 is revised to read as follows:
- 1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.
- (a) The computer readable form required by 1.021(c) shall meet the following specifications:
- (1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media: outlined in paragraph (c) of this section.
- (2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.
- (3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.
- (4) File compression is acceptable when using disflette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.
- (5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" (ile.
- (6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.
- (b) Computer readable form submissions must meet these format requirements:
- (1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;
- (2) Operating System: MS-DOS, Unix or Macintosh;